Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitafloxacin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitafloxacin Anhydrous SCHEMBL29391142 | 1.00 | POLB (0.58) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL30429200 | 1.00 | POLB (0.58) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL28146553 | 1.00 | POLB (0.58) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL1652843 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL21416358 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL74553 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL29368438 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL13483604 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL29821427 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL8509346 | 0.99 | ALDH1A1 (0.59) | POLBALDH1A1CHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195761-B | Preparation method of high-purity sitafloxacin hydrate 3/2 | 浙江普洛家园药业有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113181125-B | Sitafloxacin hydrate tablet and preparation method thereof | 海南通用三洋药业有限公司 | 2022-07-19 | — | — | CN | claimed |
| CN-113181125-A | Sitafloxacin hydrate tablet and preparation method thereof | 海南通用三洋药业有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-112915068-A | Sitafloxacin fine granule and preparation process thereof | 济川药业集团有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-110790744-A | Pyridonecarboxylic acid derivatives, process for preparing same and compositions containing same | 南京优科生物医药研究有限公司 | 2020-02-14 | — | — | CN | claimed |
| CN-105663054-B | A kind of Sitafloxacin hydrate granules agent and preparation method thereof | 济川药业集团有限公司 | 2018-06-12 | — | — | CN | claimed |
| CN-107513053-A | A kind of preparation method of sitafloxacin hydrate | 江苏吴中医药集团有限公司 | 2017-12-26 | — | — | CN | claimed |
| CN-105663054-A | Sitafloxacin hydrate granules and preparation method of sitafloxacin hydrate granules | 济川药业集团有限公司 | 2016-06-15 | — | — | CN | claimed |
| CN-105061395-A | Preparation method of sitafloxacin hydrate | JIANGSU WUZHONG PHARMACEUTICAL GROUP CORP | 2015-11-18 | — | — | CN | claimed |
| CN-102988298-B | Preparation method of sitafloxacin hydrate granule composition | SUN JIANLING | 2014-03-19 | — | — | CN | claimed |
| US-20110159049-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-06-30 | — | — | US | claimed |
| CN-1343128-B | Medicinal compositions | DAICHI PHARMACEUTICAL CO LTD | 2010-04-21 | — | — | CN | claimed |
| CN-101637447-A | Sitafloxacin hydrate injection and preparation method thereof | WUHAN WUYAO TECHNOLOGY CO LTD | 2010-02-03 | — | — | CN | claimed |
| CN-101491496-A | Sitafloxacine injection and preparation method thereof | WUHAN YAOGU TECHNOLOGY DEV CO (CN) | 2009-07-29 | — | — | CN | claimed |
| CN-101390841-A | Sitafloxacin hydrate tablet and preparation method thereof | WUHAN YAOGU TECHNOLOGY DEV CO (CN) | 2009-03-25 | — | — | CN | claimed |
| CN-101385720-A | Sitafloxacin hydrate capsules and preparation method thereof | WUHAN YAOGU TECHNOLOGY DEV CO (CN) | 2009-03-18 | — | — | CN | claimed |
| CN-101385716-A | Sitafloxacin hydrate granules and preparation method thereof | WUHAN YAOGU TECHNOLOGY DEV CO (CN) | 2009-03-18 | — | — | CN | claimed |
| EP-1085891-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064054-A9 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999064054-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159049-A1 | PHARMACEUTICAL COMPOSITION | TAS2R5, TAS2R60, TAS2R16 | POLB 3322/4885ALDH1A1 4071/4885CHRM2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.